Source: Eur Respir J, 55 (5) 1902272; 10.1183/13993003.02272-2019
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Samara M.A. Jansen, Lieke van den Heuvel, Lilian J. Meijboom, Suzanne I.M. Alsters, Anton Vonk Noordegraaf, Arjan Houweling, Harm Jan Bogaard. Correspondence regarding “T-box protein 4 mutation causing pulmonary arterial hypertension and lung disease”: a single-centre case series. Eur Respir J, 55 (5) 1902272; 10.1183/13993003.02272-2019

Member's Comments

No comment yet.

Related content which might interest you: T-box protein 4 mutation causing pulmonary arterial hypertension and lung disease Source: Eur Respir J, 54 (2) 1900388; 10.1183/13993003.00388-2019 Year: 2019 CFTR and risk of pulmonary arterial hypertension: a case report and mendelian randomization study Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension Year: 2020 Observational retrospective study on the treatment of pulmonary hypertension (PH) associated to pulmonary disease in patient with PH out of proportion Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Pulmonary arterial hypertension related with congenital heart disease (PAH r-CHD): a retrospective study of 21 patients Source: Annual Congress 2009 - Pulmonary circulation Year: 2009 Recurrent thromboembolism and pulmonary hypertension secondary to protein S deficiency (a case report) Source: Eur Respir J 2002; 20: Suppl. 38, 237s Year: 2002 Prevalence of pulmonary arterial hypertension in idiopathic pulmonary fibrosis: a multicenter study Source: Eur Respir J 2007; 30: Suppl. 51, 119s Year: 2007 Genetics of pulmonary hypertension: from bench to bedside Source: Eur Respir J 2002; 20: 741-749 Year: 2002 Pulmonary arterial hypertension preceding idiopathic pulmonary fibrosis in a BMPR2 mutation positive patient Source: Eur Respir Rev 2014; 23: 147-149 Year: 2014 Pulmonary arterial hypertension (PAH) in primary Sjögren‘s syndrome: report of 9 cases Source: Eur Respir J 2007; 30: Suppl. 51, 344s Year: 2007 Treatment of severe pulmonary hypertension secondary to chronic lung disease: A multicentre study. Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020 Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases Source: Eur Respir J 2008; 31: 343-348 Year: 2008 Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry Source: Eur Respir J, 58 (2) 2101483; 10.1183/13993003.01483-2021 Year: 2021 First identification of Krüppel-like factor 2 mutation in heritable pulmonary arterial hypertension Source: International Congress 2017 – Current molecular and genetic understanding of lung diseases Year: 2017 Clinical manifestation of hereditary pulmonary arterial hypertension by a ²second hit² mutation in the genes BMPR2 and EIF2AK4 Source: International Congress 2016 – Pulmonary hypertension: the clinic I Year: 2016 Pulmonary hypertension and pulmonary vascular disease: course report Source: Breathe, 14 (1) e4; 10.1183/20734735.019917 Year: 2018 Diffuse lung disease and pulmonary hypertension related to TBX4 mutation in 5 children Source: International Congress 2019 – A mixture of rare lung diseases Year: 2019 Phenotype of patients with severe pulmonary hypertension secondary to chronic obstructive pulmonary disease: A multicentre study. Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020 Phenotype and outcome of pulmonary arterial hypertension patients carrying a TBX4 mutation Source: Eur Respir J, 55 (5) 1902340; 10.1183/13993003.02340-2019 Year: 2020 Hemodynamics and response to therapy of pulmonary hypertension in patients with interstitial lung disease: Preliminary results of the "HYPID" prospective study Source: Annual Congress 2012 - Pulmonary circulation: clinical treatment Year: 2012